DVB Bank’s Aviation Investment and Asset Management Business to Be Acquired by SVPGlobal and EnTrust Global
11.3.2021 15:00:00 EET | Business Wire | Press release
The Blue Sky Aviation strategy managed by EnTrust Global (“EnTrust”), a leading alternative asset management firm, and funds managed by Strategic Value Partners, LLC and its affiliates ("SVPGlobal"), a global investment firm, have today announced that they have entered into a definitive agreement to acquire the Aviation Investment and Asset Management business (the “Business”) from DVB Bank Group. The transaction is expected to close during the first half of 2021.
The Business, one of the top 10 aviation service companies globally, will be acquired through a newly incorporated UK company, Deucalion Aviation Limited (“Deucalion” or the “Company”). Today, the Business is a global aviation management platform that provides comprehensive turnkey solutions for financial investors looking to deploy capital in aircraft assets, through origination, structuring, execution, fund management and a full-fledged range of servicing activities, including aircraft remarketing, technical management, lease management and consultancy. The 45-strong team manages approximately 160 aircraft on lease to more than 80 airlines globally, representing approximately $5 billion in total asset value.
EnTrust and SVPGlobal’s investment is expected to provide the support required by the existing management team to build on its international growth strategy and explore complementary opportunities arising from the current aviation industry dislocation.
Deucalion, which will be led jointly by Jon Skirrow and Stephan Sayre, will be acquired through a joint venture formed between EnTrust and SVPGlobal, utilising the two firms’ complementary expertise. Senior members of the EnTrust Blue Sky Aviation and SVPGlobal teams have worked together on various transactions over the past 15 years.
Jon Skirrow said: “We are delighted to be partnering with EnTrust and SVPGlobal, following many successful years with DVB Bank Group. This new investment will support us in capitalizing on our strong growth trajectory, and we look forward to continuing to provide our world-leading services to our clients as we embark on the next stage of our development.”
Stephan Sayre added: “EnTrust and SVPGlobal, who share our vision of the opportunities in this sector today and in the long term, enable us not only to reinforce our commitment to providing best-in-class service for our clients, but also to significantly strengthen our offering of a broad array of innovative financing solutions to airline and leasing clients globally in the current environment.”
Victor Khosla, Founder & CIO of SVPGlobal, said: “This is an innovative platform with world class aviation expertise and an excellent track record in managing complex, large and unique projects across diversified asset types and structures over the last 17 years. Our investment as part of this joint venture with EnTrust is a testament to the sizeable market opportunity set we see ahead for the business.”
John Morabito, Senior Managing Director and Portfolio Manager of EnTrust Global’s Blue Sky Aviation strategy, said: “As we continue to build a multi-faceted, relative value investment platform in the aviation industry, this acquisition enhances EnTrust’s Blue Sky Aviation strategy with the full service capabilities critical to providing a wide offering of solutions to constituents within the market. We look forward to the opportunity to partner with SVPGlobal and the talented DVB management team, with whom our team has a long-standing relationship.”
About DVB
DVB Bank SE is a financial services provider specialising in international transport finance. With 329 employees and offices worldwide, the Bank manages a loan portfolio worth €3.9 billion. As an affiliate of DZ BANK AG Deutsche Zentral-Genossenschaftsbank, Frankfurt am Main, DVB is part of Germany's second-largest banking group. Please visit our website www.dvbbank.com for additional information.
About EnTrust Global
EnTrust Global is a leading alternative asset management firm with approximately $19 billion in total assets*. Co-founded in 1997 by Chairman and CEO Gregg S. Hymowitz, the firm manages assets for over 500 institutional investors representing 47 countries and has approximately $10 billion in customized strategic partnerships. EnTrust Global offers a diverse range of alternative investment opportunities across strategies, including private debt and real assets as well as opportunistic co-investments and direct investments. EnTrust Global has 11 offices worldwide and is headquartered in New York and London.
*As of September 30, 2020. Based on estimates and includes assets under advisement and mandates awarded but not yet funded.
About Strategic Value Partners
SVPGlobal is a global investment firm with approximately $11 billion in assets under management. The firm, established by Victor Khosla in 2001, has 127 employees, including 49 investment professionals, across its main offices in Greenwich (CT), London and Tokyo. Learn more at www.svpglobal.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210311005339/en/
Contact information
DVB
Stephan Sayre
Stephan.Sayre@dvbbank.com
+44 207 2564 344
Jon Skirrow
Jon.Skirrow@dvbbank.com
+44 207 2564 430
EnTrust Global
Hiltzik Strategies
Meghan Kilkenny, Chris Cunningham
EnTrust@hstrategies.com
+1 (212) 792-9338
SVPGlobal
–
Europe
Greenbrook Communications
James Madsen, Mikaela Murekian, Fanni Bodri
svp@greenbrookpr.com
+44 20 7952 2000
SVPGlobal – North America
Kekst CNC
Todd Fogarty, Richard Goldman
SVPGlobal@kekstcnc.com
+1 (212) 521-4800
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 14:30:00 EEST | Press release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
